
[PRESS RELEASE] – NORWOOD, Mass., June 25, 2026 – MariMed Inc., a leading multistate cannabis operator, announced that the company submitted applications with the U.S. Drug Enforcement Administration (DEA) to register certain state-licensed medical cannabis operations.
Registering the company’s medical cannabis licenses with the DEA is a requirement to qualify for the protections provided by the federal rescheduling of medical marijuana to Schedule III of the Controlled Substances Act.
“DEA registration of certain of our medical businesses marks an important step forward for MariMed as we move the company toward becoming a federally legal business,” MariMed CEO Jon Levine said.




















